Oslif Breezhaler (Indacaterol)

Indacaterol is a long‑acting β2‑agonist indicated for maintenance therapy in chronic obstructive pulmonary disease and related conditions.

• COPD: improves lung function and reduces the frequency of exacerbations.
• Chronic bronchitis: provides sustained bronchodilation to ease airflow limitation.
• Emphysema: helps maintain airway patency and supports symptom control.

• Indacaterol selectively stimulates β2‑adrenergic receptors on airway smooth muscle, leading to activation of adenylate cyclase and increased cyclic AMP levels. Elevated cAMP causes relaxation of bronchial smooth muscle, resulting in prolonged bronchodilation and improved airflow in patients with obstructive lung disease.

Indacaterol may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects

• Cough: mild to moderate irritation of the throat.
• Nasopharyngitis: inflammation of the nasal passages and throat.
• Headache: occasional mild headache.
• Throat irritation: sensation of dryness or soreness.
• Upper respiratory tract infection: mild cold‑like symptoms.

Serious or Rare Side Effects

• Paradoxical bronchospasm: sudden worsening of breathing.
• Hypersensitivity reactions: rash, itching, or swelling.
• Angioedema: swelling of the face, lips, or tongue.
• Cardiovascular events: tachyarrhythmia or significant hypertension.

Before prescribing indacaterol, clinicians should consider patient‑specific factors and monitor for potential risks.

• Cardiovascular assessment: evaluate for existing heart disease before use.
• Paradoxical bronchospasm: advise patients to seek immediate help if breathing worsens.
• Hepatic impairment: use with caution in severe liver disease.
• Electrolyte balance: monitor potassium levels, especially if diuretics are used.
• β‑blocker use: avoid concurrent non‑selective β‑blockers as they may reduce efficacy.
• Store at ambient temperature: keep in the original pack, protect from moisture and heat.

Indacaterol can interact with several drug classes; some combinations require avoidance while others need close monitoring.

Major Interactions (Avoid)

• Non‑selective β‑blockers: may antagonize bronchodilator effect and precipitate bronchospasm.
• Other long‑acting β2‑agonists: increase risk of cardiovascular adverse events.
• Monoamine oxidase inhibitors (MAOIs): potential for exaggerated sympathomimetic effects.

Moderate Interactions (Monitor Closely)

• Inhaled corticosteroids: heightened risk of pneumonia in COPD patients.
• Diuretics: may exacerbate hypokalemia, increasing arrhythmia risk.
• Theophylline: possible additive stimulant effects on the heart.